TODD E SIMPSON Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for TODD E SIMPSON.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of TODD E SIMPSON. TODD E SIMPSON is VP, CFO, Treas. & Sec. in AmpliPhi Biosciences Corp ($APHB) and Chief Financial Officer in SEATTLE GENETICS INC /WA ($SGEN) and See Remarks in SEATTLE GENETICS INC /WA ($SGEN) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP).
Latest Insider Trading Transactions of TODD E SIMPSON
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, APHB, NLTX, SGEN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | NLTX | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| Dec 18 2020 | SGEN | Seagen Inc. | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 26.10 | 33,669 | 878,761 | 0 | |
| Dec 18 2020 | SGEN | Seagen Inc. | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 45.30 | 1,104 | 50,011 | 0 | |
| Dec 18 2020 | SGEN | Seagen Inc. | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 45.30 | 1,104 | 50,011 | 119,871 | 118.8 K to 119.9 K (+0.93 %) |
| Dec 18 2020 | SGEN | Seagen Inc. | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 200.00 | 33,669 | 6,733,800 | 118,767 | 152.4 K to 118.8 K (-22.09 %) |
| Dec 18 2020 | SGEN | Seagen Inc. | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 26.10 | 33,669 | 878,761 | 152,436 | 118.8 K to 152.4 K (+28.35 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 159.33 | 469 | 74,726 | 126,276 | 126.7 K to 126.3 K (-0.37 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 157.82 | 50 | 7,891 | 126,745 | 126.8 K to 126.7 K (-0.04 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 156.87 | 1,640 | 257,267 | 126,795 | 128.4 K to 126.8 K (-1.28 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 155.74 | 5,480 | 853,455 | 128,435 | 133.9 K to 128.4 K (-4.09 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 155.25 | 4,452 | 691,173 | 133,915 | 138.4 K to 133.9 K (-3.22 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 155.69 | 2,122 | 330,383 | 138,367 | 140.5 K to 138.4 K (-1.51 %) |
| Sep 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 155.69 | 2,065 | 321,509 | 140,489 | 142.6 K to 140.5 K (-1.45 %) |
| Aug 20 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 158.17 | 9,262 | 1,464,959 | 142,554 | 151.8 K to 142.6 K (-6.10 %) |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 20,774 | 3,361,649 | 20,774 | |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 8,635 | 0 | 151,816 | 143.2 K to 151.8 K (+6.03 %) |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 20,774 | 3,361,649 | 20,774 | |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 161.82 | 636 | 102,918 | 636 | |
| Aug 17 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 8,635 | 0 | 151,816 | 143.2 K to 151.8 K (+6.03 %) |
| Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 166.74 | 1,905 | 317,640 | 143,181 | 145.1 K to 143.2 K (-1.31 %) |
| Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 166.10 | 10,375 | 1,723,288 | 145,086 | 155.5 K to 145.1 K (-6.67 %) |
| Aug 05 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 164.96 | 7,720 | 1,273,491 | 155,461 | 163.2 K to 155.5 K (-4.73 %) |
| Jul 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 171.39 | 1,010 | 173,104 | 163,181 | 164.2 K to 163.2 K (-0.62 %) |
| Jul 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 170.18 | 139 | 23,655 | 164,191 | 164.3 K to 164.2 K (-0.08 %) |
| Jul 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 167.66 | 5,012 | 840,312 | 164,330 | 169.3 K to 164.3 K (-2.96 %) |
| Jul 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 166.99 | 4,112 | 686,663 | 169,342 | 173.5 K to 169.3 K (-2.37 %) |
| Jul 02 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 165.86 | 1,300 | 215,618 | 173,454 | 174.8 K to 173.5 K (-0.74 %) |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 15.46 | 26,867 | 415,364 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 12.00 | 14,167 | 170,004 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 45.30 | 1,103 | 49,966 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 44.09 | 2,268 | 99,996 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 41.04 | 2,436 | 99,973 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 39.15 | 2,554 | 99,989 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 26.10 | 3,831 | 99,989 | 0 | |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 26.10 | 3,831 | 99,989 | 173,888 | 170.1 K to 173.9 K (+2.25 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 41.04 | 2,436 | 99,973 | 170,057 | 167.6 K to 170.1 K (+1.45 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 44.09 | 2,268 | 99,996 | 167,621 | 165.4 K to 167.6 K (+1.37 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 39.15 | 2,554 | 99,989 | 165,353 | 162.8 K to 165.4 K (+1.57 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 45.30 | 1,103 | 49,966 | 162,799 | 161.7 K to 162.8 K (+0.68 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 164.10 | 1,200 | 196,920 | 161,696 | 162.9 K to 161.7 K (-0.74 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 163.36 | 12,167 | 1,987,601 | 162,896 | 175.1 K to 162.9 K (-6.95 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 162.45 | 13,500 | 2,193,075 | 175,063 | 188.6 K to 175.1 K (-7.16 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 15.46 | 26,867 | 415,364 | 188,563 | 161.7 K to 188.6 K (+16.62 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 147.00 | 14,167 | 2,082,556 | 161,696 | 175.9 K to 161.7 K (-8.06 %) |
| May 06 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 12.00 | 14,167 | 170,004 | 175,863 | 161.7 K to 175.9 K (+8.76 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | D | 139.92 | 570 | 79,752 | 161,696 | 162.3 K to 161.7 K (-0.35 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 1,439 | 0 | 162,266 | 160.8 K to 162.3 K (+0.89 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 2,389 | 0 | 160,827 | 158.4 K to 160.8 K (+1.51 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | D | 139.92 | 570 | 79,752 | 161,696 | 162.3 K to 161.7 K (-0.35 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 1,439 | 0 | 162,266 | 160.8 K to 162.3 K (+0.89 %) |
| Apr 21 2020 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 2,389 | 0 | 160,827 | 158.4 K to 160.8 K (+1.51 %) |
| Dec 23 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 871 | 0 | 158,438 | 157.6 K to 158.4 K (+0.55 %) |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 02 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 85.00 | 15,000 | 1,275,000 | 157,567 | 172.6 K to 157.6 K (-8.69 %) |
| Sep 04 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | See Remarks | Option Exercise | A | 72.64 | 49,232 | 3,576,212 | 49,232 | |
| Sep 04 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | See Remarks | Option Exercise | A | 72.64 | 1,333 | 96,829 | 1,333 | |
| Sep 04 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | See Remarks | Sell | S | 70.80 | 2,092 | 148,112 | 172,567 | 174.7 K to 172.6 K (-1.20 %) |
| Sep 04 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | See Remarks | Grant | A | 0.00 | 21,288 | 0 | 174,659 | 153.4 K to 174.7 K (+13.88 %) |
| Aug 30 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 73.21 | 5,909 | 432,624 | 153,371 | 159.3 K to 153.4 K (-3.71 %) |
| Aug 22 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 80.00 | 12,500 | 1,000,000 | 159,280 | 171.8 K to 159.3 K (-7.28 %) |
| Apr 09 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 78.00 | 10,437 | 814,086 | 171,780 | 182.2 K to 171.8 K (-5.73 %) |
| Apr 09 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 78.00 | 2,063 | 160,914 | 182,217 | 184.3 K to 182.2 K (-1.12 %) |
| Apr 09 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 78.00 | 10,437 | 814,086 | 171,780 | 182.2 K to 171.8 K (-5.73 %) |
| Apr 09 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 78.00 | 2,063 | 160,914 | 182,217 | 184.3 K to 182.2 K (-1.12 %) |
| Mar 06 2019 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 75.00 | 10,000 | 750,000 | 184,280 | 194.3 K to 184.3 K (-5.15 %) |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 76.86 | 47,904 | 3,681,901 | 47,904 | |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 76.86 | 1,301 | 99,995 | 1,301 | |
| Sep 04 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 20,715 | 0 | 194,280 | 173.6 K to 194.3 K (+11.94 %) |
| Aug 29 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 74.23 | 5,427 | 402,856 | 173,565 | 179 K to 173.6 K (-3.03 %) |
| Aug 29 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 74.23 | 5,427 | 402,856 | 173,565 | 179 K to 173.6 K (-3.03 %) |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| Mar 22 2018 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 34.20 | 10,526 | 359,989 | 10,526 | |
| Nov 03 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 61.59 | 534 | 32,889 | 178,992 | 179.5 K to 179 K (-0.30 %) |
| Nov 03 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 60.90 | 38,851 | 2,366,026 | 179,526 | 218.4 K to 179.5 K (-17.79 %) |
| Sep 08 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 52.00 | 9,638 | 501,176 | 218,377 | 228 K to 218.4 K (-4.23 %) |
| Aug 30 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 47.89 | 4,937 | 236,455 | 228,015 | 233 K to 228 K (-2.12 %) |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 46.37 | 55,344 | 2,566,301 | 55,344 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 46.37 | 2,156 | 99,974 | 2,156 | |
| Aug 18 2017 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 23,000 | 0 | 232,952 | 210 K to 233 K (+10.95 %) |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 45.30 | 42,793 | 1,938,523 | 42,793 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 45.30 | 2,207 | 99,977 | 2,207 | |
| Aug 30 2016 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 18,000 | 0 | 209,445 | 191.4 K to 209.4 K (+9.40 %) |
| Aug 22 2016 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 46.59 | 3,991 | 185,943 | 191,445 | 195.4 K to 191.4 K (-2.04 %) |
| May 11 2016 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 7.73 | 7,500 | 57,975 | 7,500 | |
| Oct 01 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 15.46 | 6,468 | 99,995 | 0 | |
| Oct 01 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | M | 12.00 | 8,333 | 99,996 | 0 | |
| Oct 01 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 12.00 | 8,333 | 99,996 | 194,675 | 186.3 K to 194.7 K (+4.47 %) |
| Oct 01 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Buy | M | 15.46 | 6,468 | 99,995 | 186,342 | 179.9 K to 186.3 K (+3.60 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 39.15 | 39,946 | 1,563,886 | 39,946 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Option Exercise | A | 39.15 | 2,554 | 99,989 | 2,554 | |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Grant | A | 0.00 | 17,000 | 0 | 179,874 | 162.9 K to 179.9 K (+10.44 %) |
| Aug 25 2015 | SGEN | SEATTLE GENETICS I ... | SIMPSON TODD E | Chief Financial Off ... | Sell | S | 42.02 | 5,825 | 244,794 | 162,874 | 168.7 K to 162.9 K (-3.45 %) |
| Mar 16 2015 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 12.03 | 5,000 | 60,150 | 5,000 | |
| May 26 2005 | APHB | AmpliPhi Bioscienc ... | SIMPSON TODD E | VP, CFO, Treas. & S ... | Option Exercise | A | 0.91 | 75,000 | 68,250 | 75,000 | |
| May 24 2004 | APHB | AmpliPhi Bioscienc ... | SIMPSON TODD E | VP, CFO, Treas. & S ... | Option Exercise | A | 1.31 | 150,000 | 196,500 | 150,000 |
Page: 1